Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.45	0.42	-	-	-	-
Cost of Revenue	-	-	-	-	-	4.66
Gross Profit	0.45	0.42	-	-	-	-4.66
Selling, General & Admin	6.66	6.72	7.38	7.46	5.88	5.02
Research & Development	16.28	19.16	20.27	14.93	4.76	-
Operating Expenses	22.94	25.87	27.66	22.39	10.64	5.02
Operating Income	-22.49	-25.45	-27.66	-22.39	-10.64	-9.68
Interest & Investment Income	0.15	0.27	0.21	0.02	0.04	0.22
Currency Exchange Gain (Loss)	-0.33	-0.41	0.23	0.04	0.02	0.1
Other Non Operating Income (Expenses)	-0.06	0.05	1.3	0.14	0.89	0.23
EBT Excluding Unusual Items	-22.73	-25.55	-25.92	-22.19	-9.68	-9.13
Pretax Income	-22.73	-25.55	-25.92	-22.19	-9.68	-9.13
Income Tax Expense	-3.03	-3	-4.72	-3.73	-1.24	-1.3
Earnings From Continuing Operations	-19.7	-22.56	-21.2	-18.46	-8.45	-7.83
Net Income	-19.7	-22.56	-21.2	-18.46	-8.45	-7.83
Preferred Dividends & Other Adjustments	0.15	0.2	0.2	0.2	3.98	0.2
Net Income to Common	-19.85	-22.76	-21.4	-18.66	-12.42	-8.03
Shares Outstanding (Basic)	1	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	1	0	0
Shares Change (YoY)	21.86%	13.38%	26.10%	145.67%	345.23%	34.95%
EPS (Basic)	-20.54	-26.75	-28.52	-31.35	-51.28	-147.62
EPS (Diluted)	-20.54	-26.75	-28.52	-31.35	-51.30	-147.62
Free Cash Flow	-9.73	-16.12	-20.83	-18.57	-8.03	-9.46
Free Cash Flow Per Share	-10.07	-18.94	-27.76	-31.20	-33.15	-173.83
Gross Margin	100.00%	100.00%	-	-	-	-
Operating Margin	-5008.69%	-6060.24%	-	-	-	-
Free Cash Flow Margin	-2167.93%	-3837.62%	-	-	-	-
EBITDA	-22.46	-25.42	-27.62	-22.35	-10.62	-9.66
D&A For EBITDA	0.03	0.03	0.03	0.04	0.02	0.02
EBIT	-22.49	-25.45	-27.66	-22.39	-10.64	-9.68
Revenue as Reported	0.42	0.42	-	-	-	-

Source: S&P Capital IQ. Standard template.